Espinoza-Hernández JD

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 41-42
Archivo PDF: 128.27 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fearon WF, Zimmermann FM, De Bruyne B, et al.; FAME 3 Investigators. FractionalFlow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. NEngl J Med. 2022;386(2):128-137. doi: 10.1056/NEJMoa2112299.

2. Neumann FJ, Sousa-Uva M, Ahlsson A, et al.; ESC Scientific Document Group.2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J.2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394.

3. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guidelinefor Coronary Artery Revascularization: Executive Summary: A Report of theAmerican College of Cardiology/American Heart Association Joint Committeeon Clinical Practice Guidelines. Circulation. 2022;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039.

4. Serruys PW, Morice MC, Kappetein AP, et al.; SYNTAX Investigators. Percutaneouscoronary intervention versus coronary-artery bypass grafting for severecoronary artery disease. N Engl J Med. 2009;360(10):961-972. doi: 10.1056/NEJMoa0804626.

5. Stone GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or CABGfor left main coronary disease. N Engl J Med 2019; 381:1820-1830.DOI: 10.1056/NEJMc2000645.

6. Mäkikallio T, Holm NR, Lindsay M, et al.; NOBLE study investigators. Percutaneouscoronary angioplasty versus coronary artery bypass grafting in treatment ofunprotected left main stenosis (NOBLE): a prospective, randomised, open-label,non-inferiority trial. Lancet. 2016;388(10061):2743-2752. doi: 10.1016/S0140-6736(16)32052-9.

7. Farkouh ME, Domanski M, Sleeper LA, et al.; FREEDOM Trial Investigators.Strategies for multivessel revascularization in patients with diabetes. N Engl JMed. 2012;367(25):2375-2384. doi: 10.1056/NEJMoa1211585.